Cotignola

Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with Kalios TM , adjustable mitral ring, in the treatment of mitral regurgitation.

Retrieved on: 
Mardi, juillet 26, 2022
Association, Pathology, Death, Physician, European Association for Cardio-Thoracic Surgery, Regulatory News Service, ISIN, Trial of the century, Wealth, CEO, Learning curve, Adrenal insufficiency, Degenerative disease, Associate, Mitral insufficiency, Safety, Classification, Medical University of Vienna, Recurrence, Company, Urinary incontinence, Patient, Heart, Life, Department, Heart failure, Medical school, Ticker, Mitral valve repair, NYHA, Pharmaceutical industry, Medical imaging, Telescopic sight, Medical device, Hospital, Cotignola, Medtech

Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with Kalios TM , adjustable mitral ring, in the treatment of mitral regurgitation.

Key Points: 
  • Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with Kalios TM , adjustable mitral ring, in the treatment of mitral regurgitation.
  • Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with KaliosTM, adjustable mitral ring, in the treatment of mitral regurgitation
    Affluent Medical (ISIN code: FR0013333077 Ticker: AFME), a French medtech specializing in the international development and industrialisation of innovative medical prostheses, at a clinical stage, to treat cardiac mitral valve pathology and urinary incontinence, today reports excellent safety and performance interim result of its Optimize II pivotal study with KaliosTM adjustable mitral ring.
  • KaliosTM also would have the potential to improve the longer-term treatment of recurrent mitral regurgitation.
  • Today we report interim data of the first 16 patients with analysis completed in May 2022 from our pivotal Optimize II study.

Affluent Medical : Financial results for the first half of 2021 and main clinical update.

Retrieved on: 
Mercredi, septembre 22, 2021
ESC, Man, Review, American College of Cardiology, Feedback, FCCP, Death, University, Icahn School of Medicine at Mount Sinai, Silver, Cotignola, Degenerative disease, University of Paris, Mitral valve, FAHA, Heart, Neuro, Group, Education, Committee, Journal, IFRS, Andreas, Cardiovascular disease, Urinary incontinence, EAU, Professor, Company, FESC, Health policy, BJU International, Kalio, Mehran, SAIME, NYHA, The Journal of Urology, Surgeon, COVID-19, Patient, FACC, FACP, American College, Ethics, Adrenal insufficiency, Nature Reviews Urology, Trial of the century, Mount Sinai Hospital, IPO, European Urology, Artus, Animal, Security (finance), Medical device, Pharmaceutical industry, Medicine

During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.

Key Points: 
  • During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.
  • On 9 June 2021, Affluent Medical announced the success of its IPO on the regulated market of Euronext Paris.
  • Starting in 2018 he broadened his field of expertise by engaging in various entrepreneurial projects before joining Affluent Medical.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.

Neovasc Reducer™ Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

Retrieved on: 
Vendredi, novembre 22, 2019
Christian saints, Ancient Roman women, Saint Cecilia, Cotignola, 1st millennium, Ancient Romans

Additionally, on Friday, November 22, 2019, a distinguished group of physicians will feature the Reducer in a GVM Care & Research Group (the GVM Group) dedicated session at the Maria Cecilia Hospital in Cotignola (the Cotignola Sessions).

Key Points: 
  • Additionally, on Friday, November 22, 2019, a distinguished group of physicians will feature the Reducer in a GVM Care & Research Group (the GVM Group) dedicated session at the Maria Cecilia Hospital in Cotignola (the Cotignola Sessions).
  • On November 22, 2019, Professor Antonio Colombo and Doctor Giannini will chair a full day program that features the Reducer, hosted at Maria Cecilia Hospital and entitled Coronary Sinus Reducer Meeting Towards new horizons of refractory angina management.
  • GVM Group operates 23 hospitals in Italy, with Maria Cecilia being the first hospital it founded in the 1970s.
  • "We are honored that an eminent institution like GVM Group is supporting the therapy and is hosting a full day program featuring Reducer.

Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto™ Intravascular Imaging System

Retrieved on: 
Lundi, avril 22, 2019
Health, Biotechnology, Cardiology, Medical devices, Pharmaceutical, FDA, Cotignola

The system utilizes NIRS to detect lipid core plaque (LCP) and automatically displays the results via a simple, color-coded map, called a chemogram.

Key Points: 
  • The system utilizes NIRS to detect lipid core plaque (LCP) and automatically displays the results via a simple, color-coded map, called a chemogram.
  • The system automatically generates LCBI calculations and the chemogram, which displays the presence of LCP in yellow and absence in red.
  • Antonio Colombo, MD,Maria Cecilia Hospital in Cotignola (Ravenna), General Coordinator GVM Hospitalsand Columbus Hospital in Milan, Italy, stated, The Makoto Imaging System significantly advances the field of intracoronary imaging.
  • Infraredx, a Nipro Company, launched the Makoto Imaging System in Japan in 2018 and will continue expansion into the US and EU markets.